Loading data for CELZ — first visit, this takes a few seconds.

Alerte

Creative Medical Technolo... (CELZ)

NasdaqCM: CELZ · Prix en temps réel · USD

1.14

+0.00 (0.00%)

À la clôture : Aug 28, 2026, 3:59 PM

Le cours, les chiffres clés et les dernières actualités, au même endroit.

0.00% (1D)

Cours acheteur	0.83
Capitalisation boursière	7.52M
Chiffre d’affaires (ttm)	3K
Résultat net (ttm)	-6.04M
	1.94
	-2.05
	n/a
	-1.3
P/B (ttm)	0.86
P/S (ttm)	2505.17
Date des résultats	n/a

Cours vendeur	1.45
Volume	198,330
Volume moy. (20D)	9,664,825
Ouverture	1.17
Clôture précédente	1.14
Fourchette du jour	1.11 - 1.18
Intervalle de 52 semaines	0.62 - 6.25
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de CELZ

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell...

[En savoir plus]

Industrie Biotechnology

Secteur Healthcare

Date d’introduction Nov 6, 2015

Employés 4

Bourse NasdaqCM

Symbole boursier CELZ

Site web https://www.creativemedicaltechnology.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Creative Medical Technology s’élevait à 6K, soit une baisse de -45.45% par rapport aux 11K de l’année précédente. Le bénéfice s’élevait à -6M, soit une hausse de 9.13%.

États financiers

Surprise sur les résultats

Creative Medical Technology a publié ses résultats trimestriels le Aug 7, 2026 :

Chiffre d’affaires de $0 est inférieur aux estimations de $0, avec -100.00% Baisse en glissement annuel.
EPS de -0.41 est inférieur aux estimations de -0.02, avec 14.58% croissance en glissement annuel.

Actualités

3 semaines il y a · InvestorsHub

Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy

The new patent allowance expands intellectual property protection around Creative Medical’s diabetes pipeline while supporting its strategy across cell-based and cell-free immunotherapy platforms. Key...

2 mois il y a · Stocktwits

These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism?

Creative Medical Technology, Baiya International Group, and GD Culture Group shares slumped to their 52-week lows amid divestiture and fundraising updates.

2 mois il y a · Proactive

Creative Medical Technology opens nationwide burn-pit data registry

Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a regulatory-approved registry that the company...

4 mois il y a · Simply Wall St.

Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long

Creative Medical Technology Holdings, Inc. ( NASDAQ:CELZ ) is possibly approaching a major achievement in its business...

9 mois il y a · Zacks

Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings ...

Page 1 de 2